Dissecting cross‐lineage tumourigenesis under p53 inactivation through single‐cell multi‐omics and spatial transcriptomics
Clinical and Translational Medicine · 2025-09 · 15 (9)
DOI: 10.1002/ctm2.70461 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, online erschienen am 31.08.2025. Verfasst von Xinru Wang und 28 weiteren Autor:innen. Beteiligte Einrichtung: Bone Marrow Transplantation Center of the First Affiliated Hospital and Center for Stem Cell and Regenerative Medicine, Zhejiang University School of…. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Carcinogenesis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 146 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program, Key R&D Program of Zhejiang.
Abstract (Originalsprache)
Background
Tumour suppressor genes, exemplified by TP53 (encoding the human p53), function as critical guardians against tumourigenesis. Germline TP53 ‐inactivating mutations underlie Li‐Fraumeni syndrome, a hereditary cancer predisposition disorder characterised by early‐onset pan‐tissue malignancies. However, the context‐dependent tumour‐suppressive mechanisms of p53 remain incompletely elucidated. This study aims to investigate the disruption of cellular homeostasis and tumourigenic mechanisms following p53 inactivation across distinct cell lineages.
Methods
Trp53 (encoding mouse p53) knockout mouse model was employed to study molecular alterations under p53‐deficient conditions. Multi‐omics analyses – including single‐cell transcriptomics, single‐cell ATAC‐seq, spatial transcriptomics, whole genome sequencing, and CUT&Tag – were integrated to construct a Trp53 functional cell landscape. Deep learning‐based gene network models were employed to reconstruct p53 regulatory networks and simulate in silico perturbations caused by p53 loss.
Results
Our analyses revealed transitional dynamics in immune, stromal, and epithelial cells from normal physiology to p53‐deficient states and subsequent tumourigenesis. These transitions implicated critical pathways such as cell cycle regulation, stress response, metabolic reprogramming, and immune modulation, displaying both lineage‐conserved and lineage‐specific features. Tumour‐prone cell populations exhibiting elevated differentiation plasticity were identified across lineages within tumourigenic trajectories. Spatial transcriptomic profiling confirmed the emergence of thymic tumour‐initiating T‐cell clusters characterised by deterministic chromatin architectural disruptions under p53‐loss pressure. Notably, we uncovered a recurrent upregulation signature of ribosomal protein genes as an early pivotal molecular event preceding malignant transformation in p53‐deficient oncogenesis. Finally, we decoded the p53 downstream regulatory network and computationally evaluated the perturbation effects of genetic inactivation at single‐cell resolution.
Conclusions
Our results elucidate the multiscale consequences of p53 inactivation while providing valuable resources for understanding tumour predisposition associated with p53‐inactivating mutations and developing clinical interception strategies. Key points Construction of a Trp53 functional cell landscape utilising single‐cell multi‐omics and spatial omics technologies. Reconstruction of p53 downstream regulatory relationships with lineage heterogeneity via machine learning‐based gene network modelling. Dissection of shared and lineage‐specific features during cross‐lineage tumourigenesis under p53 deficiency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bone Marrow Transplantation Center of the First Affiliated Hospital and Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Zhejiang Provincial Key Lab for Tissue Engineering and Regenerative Medicine, Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Regenerative Medicine, Hangzhou, Zhejiang, China.
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, Zhejiang, China.
- College of Life Sciences, Zhejiang University, Hangzhou, Zhejiang, China.
- Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
- Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China.
ORCID-Profile: Qi Zhang, Hongwei Ouyang, Xiaoping Han
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program
- Key R&D Program of Zhejiang
- Funds for Creative Research Groups of China
- Zhejiang Provincial Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Wang, X., Mei, Y., Wang, X., Wu, H., Wang, R., Zhang, P., Zhang, G., Li, J., Jiang, M., Fang, X., Ma, L., Liao, Y., Jia, D., Niu, H., Weigao, E., Chen, H., Yang, L., Zhang, S., Zhang, T., …, & Han, X. (2025). Dissecting cross‐lineage tumourigenesis under p53 inactivation through single‐cell multi‐omics and spatial transcriptomics. Clinical and Translational Medicine, 15(9). https://doi.org/10.1002/ctm2.70461
Vancouver
Wang X, Mei Y, Wang X, Wu H, Wang R, Zhang P, et al. Dissecting cross‐lineage tumourigenesis under p53 inactivation through single‐cell multi‐omics and spatial transcriptomics. Clinical and Translational Medicine. 2025;15(9). doi:10.1002/ctm2.70461
BibTeX
@article{Wang2025,
author = {Wang, Xinru and Mei, Yuqing and Wang, Xueyi and Wu, Hanyu and Wang, Renying and Zhang, Peijing and Zhang, Guodong and Li, Jiaqi and Jiang, Mengmeng and Fang, Xing and Ma, Lifeng and Liao, Yuan and Jia, Danmei and Niu, Haofu and Weigao, E and Chen, Haide and Yang, Lei and Zhang, Shuang and Zhang, Tingyue and Zhou, Yincong and Zhang, Qi and Huang, He and Ouyang, Hongwei and Chen, Ming and Liang, Tingbo and Peng, Jinrong and Wang, Jingjing and Guo, Guoji and Han, Xiaoping},
title = {Dissecting cross‐lineage tumourigenesis under p53 inactivation through single‐cell multi‐omics and spatial transcriptomics},
journal = {Clinical and Translational Medicine},
year = {2025},
volume = {15},
number = {9},
doi = {10.1002/ctm2.70461}
}
EUVIMED